Ex-Abbott reps sue for overtime wages

Share this article:

Two former Abbott Laboratories sales reps have sued the company in federal court in Chicago, claiming the drugmaker denied them overtime wages.


The lawsuit, which seeks class-action status, comes on the heels of similar lawsuits filed last year by reps against other pharmaceutical companies including AstraZeneca, Eli Lilly, Johnson & Johnson and Pfizer.


The lawsuit argues that Abbott classifies its reps as exempt under the federal Fair Labor Standards Act, meaning they are not entitled to receive overtime pay.


Under current federal labor laws, sales forces can be exempt from overtime wages. But attorneys for the plaintiffs in the case argue that drug reps often work up to 70 hours a week and should not be classified as sales people.


“Although the companies claim that the representatives are salespersons and therefore not protected by overtime laws, with some exceptions, they actually don’t sell anything,” said attorney Charles Joseph of Joseph & Herzfeld, who filed the lawsuit on behalf of the former Abbott employees. “Rather, they are tasked to influence the prescribing behaviors of doctors.”


The lawsuit is asking the court to order Abbott to start paying overtime to its pharmaceutical reps and seeks compensation to current and former employees denied overtime pay.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.